Shanghai Jiao Tong University, China
Dawei Li completed his Ph.D from Ohio State University and postdoctoral studies from Harvard University School of Medicine in the USA. He is currently a principle investigator in medicinal biotechnology at School of Pharmacy and Center for Cell Engineering and Antibody Medicine at Shanghai Jiao Tong University. He has published more than 25 papers in reputed journals and 4 approved patents. He is a board member of the Committee for Biochemical Pharmaceutics, Shanghai Pharmaceutical Association and a member of Steering Committee for Student Educational Affairs Management at Shanghai Jiao Tong University.
Temple University, USA
Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from the UCLA School of Medicine. He was an American Cancer Society postdoctoral fellow at Stanford University from 1980-82, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, Dr. Feitelson became Associate Professor of Pathology and Cell Biology and head of the Molecular Diagnostics Lab in Microbiology at Thomas Jefferson University. In 2007, Dr. Feitelson moved to Temple University, where he is now Professor of Biology. His research has been supported by NIH for more than 20 years, has more than 130 publications, and is presently head of the Professional Science Master’s program in Biotechnology at Temple University.
Abertay University, UK
Dr. Nikolai Zhelev is Professor of Medical Biotechnology and Director of CMCBR at Abertay University, Dundee, Scotland. He is also honorary professor in eight universities in UK, China and Bulgaria. Prof. Zhelev has been involved in founding four start-up biotech companies. He is author of books, patents and papers in the field of DNA damage response, cell cycle regulation and drug discovery and development in oncology and cardiology published in reputed journals such as Nature Medicine. Prof Zhelev is Managing Editor of BioDiscovery – the first open access international scientific journal in the field of Life Sciences and Medicine, published in Scotland and currently the President of the European BioDiscovery Federation.
Sojo University, Japan
Prof. Hiroshi Maeda is a world renowned expert in macromolecular therapeutics. He was successful in creating the world first polymeric drug, SMANCS, approved for treatment of hepatoma in Japan. Consequently, he discovered the concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He received MS, University of California, Fulbright Fellow, and Ph.D., M.D., Tohoku University. He published more than 450 papers in reputed journals. He was awarded Lifetime-Achievement-Award at Royal-Pharmaceutical-Society, Princess-Takamatsu-Award in Cancer Research, Tomizo-Yoshida-Award, highest award of JCA, and also selected as most cited influential scientist in pharmacology by Thomson Reuters 2014.
SNBL Clinical Pharmacology Center, USA
Peter Odeh is a Medical Laboratory Scientist/ Medical Technologist and Clinical Laboratory Scientist of international repute. He is the Vice President, Medical and Technical services of ROPAN (NIG) LTD. and also a Research Scientist with SNBL Clinical Pharmacology Center in Baltimore Maryland. He is a recipient of many awards including the International Travel Grant Award and the Gallwas Membership Grant Award of the American Association for Clinical Chemistry in Orlando Florida in the year 2002; the McAuley Silver Award for outstanding leadership and quality of work at Mercy Medical Center in Baltimore, Continuing Education Certificate of Excellence by the American Medical Technologists Institute for Education and most recently the Mother Mary Lange OSP Service Award from the Archdiocese of Baltimore. At SNBL, he worked with regulatory bodies and company staff in upgrading the clinical laboratory into a moderate to complex testing diagnostic center which is registered with COLA.
Howard University, USA
Dr. Emmanuel O. Akala is a Professor of Pharmacy and a licensed Pharmacist in USA. He earned his Ph.D. degree from the University of Manchester, England in 1986 in Pharmaceutics under the direction of Professor John Collett (Polymeric Drug Delivery Systems). He was a Senior Lecturer in Pharmaceutics at Obafemi Awolowo University, Nigeria (1987-94). At present, he is the Professor in the Department of Pharmaceutical Sciences, School of Pharmacy and director of the Laboratory for Nano-medicine, Howard University, USA. Dr. Akala has authored more than 40 peer reviewed manuscripts (journals & proceedings), several conference abstracts, and 1 patent (WO9801421). He is a co-editor of 1 published book and 1 book chapter. He is an instructor in Physical Pharmacy and Laboratory in Pharmaceutical Sciences and the coordinator/instructor in Biopharmaceutics, Pharmacokinetics, Research in Pharmaceutical Sciences, Pharmaceutical Technology and Pharmaceutical Mathematics courses offered to the professional pharmacy (Doctor of Pharmacy) students at Howard University. Dr. Akala is also a reviewer to some scientific journals: International Journal of Pharmaceutics, Biomaterials, AAPS Pharm. Sci. (an electronic journal), and Journal of Biomedical Material Research Journal of Biomedical Material Research.